Rosen Comments on Korean Pharma Companies Doing Business in the U.S.

18 April 2019 Korea Biomedical Review News
Partner David Rosen was quoted in a Korea Biomedical Review article, "How Korean pharma companies can succeed in US," about how Korean pharmaceutical and biosimilar companies can find success in America.

Rosen, speaking at BIO KOREA 2019, said it is essential for Korean companies to develop drugs with a sense of responsibility for making the products safe. He also said if such expectations are not met, the companies can receive sanctions and penalties, including regulatory enforcement action, civil monetary penalties, and criminal liability.

"Import detention is something that everyone should be afraid the most as the Food and Drug Administration can block any import of the product," he said. "Therefore, companies have to respond to all warning letters and the concerns that the FDA has, and address them."

Related Services


Top Five New Telehealth Policies in Medicare 2021 in Physician Fee Schedule
02 December 2020
Health Care Law Today
IMMEX Highlights – Sub-maquila Operations
02 December 2020
Dashboard Insights
Podcast Episode 24: Steve Cade, Partner
01 December 2020
Foley Career Perspectives
European Data Protection Board Issues Recommendations for Exports of Personal Data From the European Economic Area
01 December 2020
Privacy, Cybersecurity & Technology Law Perspectives
HCCA San Francisco Regional Conference
04 December 2020
Virtual Conference
Webinar: Massachusetts Paid Family and Medical Leave 2021
02 December 2020
CTeL Digital Health Summit 2020
01-04 December 2020
Virtual Conference
Virtual CLE Week
Every Tuesday & Thursday from December 1 - 17 2020